PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95291

Hidekazu TONOUCHI, et al.

Appln. No.: Based on PCT/JP04/018235

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: June 1, 2006 Examiner: Unknown

For: PEPTIDE INHIBITING ANGIOTENSIN CONVERTING ENZYME

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. §§ 1.97 and 1.98</u>

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/581304

AP20 Rec'd PCT/PTO 01 JUN 2006

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Based on PCT/JP04/018235

Attorney Docket No.: Q95291

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP04/018235 dated May 17, 2005), together with an English-language version (if

not already included) of at least that portion of the Communication indicating the degree of

relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 1, 2006

Mark Boland

Registration No. 32,197

2

IAP20 REC'OPCT/PTODEED PTOSERS A200603)

Substitute for Form 1449 A & B/PTO

• INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number Q95291

Complete if Known				
Application Number	Bale Con P CT (1904/5118285)			
Confirmation Number	では 301704			
Filing Date	Unknown			
First Named Inventor	Hidekazu TONOUCHI			
Art Unit	Unknown			
Examiner Name	Unknown			
Attorney Docket Number	Q95291			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number		Publication Data	
		Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	-	US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		JP	2003-511063	Α	03-25-2003	Saint Louis University	Abstract
		JP	6-279491	A	10-04-1994	The Nippon Synthetic Chemical Industry Co., Ltd.	Abstract
		JP	6-277090	A	10-04-1994	The Nippon Synthetic Chemical Industry Co., Ltd.	Abstract
		JP	6-277091	A	10-04-1994	The Nippon Synthetic Chemical Industry Co., Ltd.	Abstract
		JP	7-101982	A	04-18-1995	The Nippon Synthetic Chemical Industry Co., Ltd.	Abstract
		JP	2002-121199	A	04-23-2002	Kabushiki Kaisha Shimaya	Abstract
				1			
	•					·	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation
		F. MINERVINI, et al., "Angiotensin I-Converting-Enzyme-Inhibitory and Antibacterial Peptides from Lactobacillus helveticus PR4 Proteinase-Hydrolyzed Caseins of Milk from Six Species", Applied and Environmental Microbiology, Sept. 2003, pp. 5297-5305, Vol. 69, No. 9	
		SHOJI KANEKO, et al., "Tofu Seizo ni Okeru Koso Riyo ni Kansuru Kenkyu (Dai 3 Ho) Koso Shori ni yoru Kinosei Koka ni tsuite", Research report of Food Technology Research Institute of Nagano Prefecture, September 1, 2003, pp. 53-56, No. 31	
		International Search Report for PCT/JP04/018235 dated May 17, 2005	

Examiner Signature	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.